Products Rivaroxaban is commercially available in the form of film-coated tablets (Xarelto, Xarelto vascular). It was approved in 2008 as the first agent in the direct factor Xa inhibitor group. Low-dose Xarelto vascular, 2.5 mg, was registered in many countries in 2019. Structure and properties Rivaroxaban (C19H18ClN3O5S, Mr = 435.9 g/mol) is a pure -enantiomer … Rivaroxaban
Products Edoxaban was approved in many countries and in the United States in 2015 in film-coated tablet form (Lixiana, some countries: Savaysa). In Japan, edoxaban was approved as early as 2011. Structure and properties Edoxaban (C24H30ClN7O4S, Mr = 548.1 g/mol) is present in the drug as edoxabantosilate monohydrate, a white to pale yellow powder that … Edoxaban
Effects Antithrombotic Anticoagulant Fibrinolytic Active ingredients Salicylates: Acetylsalicylic acid 100 mg (Aspirin Cardio). P2Y12 antagonists: Clopidogrel (Plavix, generics). Prasugrel (Efient) Ticagrelor (Brilique) GP IIb/IIIa antagonists: Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) PAR-1 antagonists: Vorapaxar (Zontivity) Vitamin K antagonists (coumarins): Phenprocoumon (Marcoumar). Acenocoumarol (Sintrom) Not on sale in many countries: dicoumarol, warfarin. Heparins: Heparin sodium Heparin-Calcium … Antithrombotics
Symptoms Possible symptoms of a bruise (technical term: hematoma) include swelling, pain, inflammation, and discoloration of the skin that changes (red, blue, purple, green, yellow, brown) during the healing process. This text refers to simple and small-surface complaints that can be considered for self-medication. Causes The cause of a hematoma is blood leaking from injured … Bruise (Hematoma) Symptoms and Causes
Products Low-molecular-weight heparins are commercially available as injectable solutions, in the form of prefilled syringes, ampoules, and lancing ampoules. The active ingredients now commonly used in many countries were first approved in the late 1980s. Biosimilars are available in some countries. The active ingredients are abbreviated in English with the acronym LMWH (low molecular weight … Low-Molecular-Weight Heparins
Products Andexanet alfa was approved in the United States in 2018, in the EU in 2019, and in many countries in 2020 as a powder for the preparation of an infusion solution (Ondexxya). Structure and properties Andexanet alfa is a recombinant, modified, and enzymatically inactive factor Xa. The drug is produced by biotechnological methods. Effects … Andexanet Alfa
Products Thrombin inhibitors are commercially available in many countries in the form of infusion preparations and as capsules. The first oral thrombin inhibitor to be launched was ximelagatran (Exanta) in 2003. Due to its liver toxicity, sales had to be discontinued. Currently, the most widely used oral and direct thrombin inhibitor, dabigatran (Pradaxa), was approved … Thrombin Inhibitors
Products Apixaban has been approved in many countries since 2011 in the form of film-coated tablets (Eliquis). Structure and properties Apixaban (C25H25N5O4, Mr = 460.0 g/mol) was developed starting from razaxaban. It is an oxopiperidine and pyrazole derivative. Effects Apixaban (ATC B01AF02) has antithrombotic properties. It is an oral, direct, potent, selective, and reversible inhibitor … Apixaban
Products Direct oral anticoagulants (abbreviation: DOAKs) are commercially available in the form of film-coated tablets and capsules. By definition, they are oral drugs. Some representatives of the corresponding drug groups are also available as infusion preparations. Rivaroxaban (Xarelto) and dabigatran (Pradaxa) were the first active ingredients to be approved in 2008. The DOAKs were developed … DOAK
Symptoms The possible symptoms and signs of deep vein thrombosis include: Pain or cramping in the legs Swelling (edema), feeling of tension Warmth sensation, overheating Reddish to blue-purple discoloration of the skin Increased visibility of the superficial veins The symptoms are rather nonspecific. Deep vein thrombosis may also be asymptomatic and discovered by chance. A … Deep Vein Thrombosis
Products Direct factor Xa inhibitors are commercially available in the form of film-coated tablets and capsules. In 2008, rivaroxaban (Xarelto) was the first agent in this group to be approved in many countries and in the EU. Today, there are other drugs on the market, which are listed below. Like thrombin inhibitors, these active ingredients … Factor Xa Inhibitors
Products Betrixaban was approved in the United States in 2017 in capsule form (Bevyxxa). The drug has not yet been approved in the EU (Dexxience). Structure and properties Betrixaban (C23H22ClN5O3, Mr = 451.9 g/mol) is present in the drug as betrixaban maleate. It is a pyridine and anthranilamide derivative. Effects Betrixaban has antithrombotic properties. The … Betrixaban
